EXCLUSIVE: Adial Pharmaceuticals Announces Publication In Journal Supporting the Potential Efficacy Of AD04 For Alcohol Use Disorder
Portfolio Pulse from Vandana Singh
Adial Pharmaceuticals announced the publication of Phase 3 ONWARD study results in the European Journal of Internal Medicine, showing the efficacy of AD04 in reducing heavy drinking days among patients with specific genetic profiles. The study found minimal adverse events and high compliance, suggesting a promising treatment for alcohol use disorder.
June 20, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Adial Pharmaceuticals' AD04 demonstrated significant efficacy in reducing heavy drinking days among patients with specific genetic profiles, with minimal adverse events. This publication in a peer-reviewed journal could boost investor confidence and increase demand for AD04.
The publication of positive Phase 3 results in a peer-reviewed journal is a significant milestone for Adial Pharmaceuticals. The demonstrated efficacy and safety profile of AD04 could lead to increased investor confidence and potential market demand, positively impacting the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100